153 related articles for article (PubMed ID: 22864660)
1. Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation.
Therkildsen C; Isinger-Ekstrand A; Ladelund S; Nissen A; Rambech E; Bernstein I; Nilbert M
Fam Cancer; 2012 Dec; 11(4):579-85. PubMed ID: 22864660
[TBL] [Abstract][Full Text] [Related]
2. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
3. Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population.
Nilbert M; Wikman FP; Hansen TV; Krarup HB; Orntoft TF; Nielsen FC; Sunde L; Gerdes AM; Cruger D; Timshel S; Bisgaard ML; Bernstein I; Okkels H
Fam Cancer; 2009; 8(1):75-83. PubMed ID: 18566915
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
[TBL] [Abstract][Full Text] [Related]
5. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.
Boilesen AE; Bisgaard ML; Bernstein I
Acta Obstet Gynecol Scand; 2008; 87(11):1129-35. PubMed ID: 18972272
[TBL] [Abstract][Full Text] [Related]
6. A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.
Borelli I; Casalis Cavalchini GC; Del Peschio S; Micheletti M; Venesio T; Sarotto I; Allavena A; Delsedime L; Barberis MA; Mandrile G; Berchialla P; Ogliara P; Bracco C; Pasini B
Fam Cancer; 2014 Sep; 13(3):401-13. PubMed ID: 24802709
[TBL] [Abstract][Full Text] [Related]
7. Recurring MLH1 deleterious mutations in unrelated Chinese Lynch syndrome families in Singapore.
Yap HL; Chieng WS; Lim JR; Lim RS; Soo R; Guo J; Lee SC
Fam Cancer; 2009; 8(2):85-94. PubMed ID: 18726168
[TBL] [Abstract][Full Text] [Related]
8. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.
Win AK; Lindor NM; Winship I; Tucker KM; Buchanan DD; Young JP; Rosty C; Leggett B; Giles GG; Goldblatt J; Macrae FA; Parry S; Kalady MF; Baron JA; Ahnen DJ; Marchand LL; Gallinger S; Haile RW; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2013 Feb; 105(4):274-9. PubMed ID: 23385444
[TBL] [Abstract][Full Text] [Related]
9. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
10. Cancer risk in a cohort of subjects carrying a single mismatch repair gene mutation.
Stupart DA; Goldberg PA; Algar U; Ramesar R
Fam Cancer; 2009; 8(4):519-23. PubMed ID: 19688281
[TBL] [Abstract][Full Text] [Related]
11. MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families.
Borràs E; Pineda M; Blanco I; Jewett EM; Wang F; Teulé A; Caldés T; Urioste M; Martínez-Bouzas C; Brunet J; Balmaña J; Torres A; Ramón y Cajal T; Sanz J; Pérez-Cabornero L; Castellví-Bel S; Alonso A; Lanas A; González S; Moreno V; Gruber SB; Rosenberg NA; Mukherjee B; Lázaro C; Capellá G
Cancer Res; 2010 Oct; 70(19):7379-91. PubMed ID: 20858721
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer.
de Leon MP; Benatti P; Di Gregorio C; Losi L; Pedroni M; Ponti G; Genuardi M; Viel A; Lucci-Cordisco E; Rossi G; Roncucci L
Scand J Gastroenterol; 2007 Jun; 42(6):746-53. PubMed ID: 17505997
[TBL] [Abstract][Full Text] [Related]
13. A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families.
Pinheiro M; Pinto C; Peixoto A; Veiga I; Mesquita B; Henrique R; Baptista M; Fragoso M; Sousa O; Pereira H; Marinho C; Moreira Dias L; Teixeira MR
Genet Med; 2011 Oct; 13(10):895-902. PubMed ID: 21785361
[TBL] [Abstract][Full Text] [Related]
14. Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome patients.
Zahary MN; Kaur G; Abu Hassan MR; Singh H; Naik VR; Ankathil R
World J Gastroenterol; 2012 Feb; 18(8):814-20. PubMed ID: 22371642
[TBL] [Abstract][Full Text] [Related]
15. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
[TBL] [Abstract][Full Text] [Related]
16. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
[TBL] [Abstract][Full Text] [Related]
17. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.
Goel A; Nguyen TP; Leung HC; Nagasaka T; Rhees J; Hotchkiss E; Arnold M; Banerji P; Koi M; Kwok CT; Packham D; Lipton L; Boland CR; Ward RL; Hitchins MP
Int J Cancer; 2011 Feb; 128(4):869-78. PubMed ID: 20473912
[TBL] [Abstract][Full Text] [Related]
18. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers.
Talseth-Palmer BA; Wijnen JT; Brenne IS; Jagmohan-Changur S; Barker D; Ashton KA; Tops CM; Evans TJ; McPhillips M; Groombridge C; Suchy J; Kurzawski G; ; Spigelman A; Møller P; Morreau HM; Van Wezel T; Lubinski J; Vasen HF; Scott RJ
Int J Cancer; 2013 Apr; 132(7):1556-64. PubMed ID: 22987364
[TBL] [Abstract][Full Text] [Related]
19. Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome.
Takahashi M; Furukawa Y; Shimodaira H; Sakayori M; Moriya T; Moriya Y; Nakamura Y; Ishioka C
Fam Cancer; 2012 Dec; 11(4):559-64. PubMed ID: 22766992
[TBL] [Abstract][Full Text] [Related]
20. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
